FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308384120> ?p ?o ?g. }

• W4308384120 abstract "<h3>Background</h3> INV-1120 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2 (PGE2), an immunosuppressive mediator of tumor immune microenvironment. Objectives of this first in human study were to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), maximum tolerated dose (MTD) and recommended phase 2 dose of INV-1120. <h3>Methods</h3> Dose-escalation was based on the traditional “3+3” dose-escalation design in sequential escalating dose cohorts (15, 30, 60, 100, 150, 200 , 250, 300 mg). Dose limiting toxicity (DLT) evaluation period was 28 days. Efficacy evaluation was performed every 8 weeks by RECIST 1.1. Blood samples were collected for pharmacokinetic characterization of the treatment. <h3>Results</h3> Twenty-four patients were enrolled and treated with single-agent INV-1120 in 6 dose cohorts (15 mg, n=3; 30 mg, n=3; 60 mg, n=6; 100 mg, n=3; 150mg, n=3; 200 mg, n=6). The median age is 58.0 with the range from 20 to 80. 10 patients are male and 14 are female. Tumor types include colorectal cancer (8), lung cancer (4), parotid adenocarcinoma (2), sarcoma (2) and others (8). 7 patients had received prior CPI therapy. There were two DLTs, one at 60 mg (grade 2 duodenal ulcer) and one at 200 mg (grade 2 duodenitis). At least 1 TEAE was reported in 24 patients (100%). The most common TEAEs (all grades) were diarrhea (6 subjects, 25.0%), nausea (6, 25.0%), anemia (6, 25.0%), and fatigue (5, 20.8%). Drug-related TEAEs occurred in 13 patients (54.2%) and grade ≥3 treatment related TEAEs occurred in one patient (4.2%). Five patients (20.8%) were discontinued or interrupted for treatment due to TEAEs, and two of them due to TEAEs that were unrelated to study drug treatment. Twenty-one patients were evaluable for efficacy as of the cut-off date of May 30, 2022. Stable disease was observed in 9 of 21(42.9%) patients. Among the 9 patients with stable disease, 5 had treatment duration ≥18 weeks. INV-1120 was rapidly absorbed across all doses, and time to maximum drug concentration was observed at ~2 hours postdose. The exposure of INV-1120 appeared to increase with dose from 15 mg to 100/150 mg and plateaued thereafter. There is no PD markers data available currently. <h3>Conclusions</h3> Single agent INV-1120 was generally well tolerated and showed prolonged stable disease. Preclinical data showing the efficacy synergy when INV-1120 combining with anti PD-1 support phase Ib protocol amendment about INV-1120 in combination with anti PD-1, and the dose escalation of the combination study will explore INV 1120 at 60, 100 and 150mg QD. <h3>Trial Registration</h3> Clinical trial registry number: NCT04443088. <h3>Ethics Approval</h3> <h3>Ethics statement: </h3> This study was approved by IntegReview IRB." @default.
• W4308384120 created "2022-11-11" @default.
• W4308384120 creator A5014206402 @default.
• W4308384120 creator A5057503413 @default.
• W4308384120 creator A5068806728 @default.
• W4308384120 creator A5070570779 @default.
• W4308384120 creator A5071894027 @default.
• W4308384120 creator A5080338388 @default.
• W4308384120 date "2022-11-01" @default.
• W4308384120 modified "2023-10-18" @default.
• W4308384120 title "597 Preliminary safety, efficacy and pharmacokinetic results of the EP4 antagonist INV-1120 from a first-in-human study in subjects with advanced solid tumors" @default.
• W4308384120 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0597" @default.
• W4308384120 hasPublicationYear "2022" @default.
• W4308384120 type Work @default.
• W4308384120 citedByCount "0" @default.
• W4308384120 crossrefType "proceedings-article" @default.
• W4308384120 hasAuthorship W4308384120A5014206402 @default.
• W4308384120 hasAuthorship W4308384120A5057503413 @default.
• W4308384120 hasAuthorship W4308384120A5068806728 @default.
• W4308384120 hasAuthorship W4308384120A5070570779 @default.
• W4308384120 hasAuthorship W4308384120A5071894027 @default.
• W4308384120 hasAuthorship W4308384120A5080338388 @default.
• W4308384120 hasBestOaLocation W43083841201 @default.
• W4308384120 hasConcept C111113717 @default.
• W4308384120 hasConcept C112705442 @default.
• W4308384120 hasConcept C126322002 @default.
• W4308384120 hasConcept C126894567 @default.
• W4308384120 hasConcept C197934379 @default.
• W4308384120 hasConcept C2778248108 @default.
• W4308384120 hasConcept C2778375690 @default.
• W4308384120 hasConcept C2780580376 @default.
• W4308384120 hasConcept C71924100 @default.
• W4308384120 hasConcept C90924648 @default.
• W4308384120 hasConcept C98274493 @default.
• W4308384120 hasConceptScore W4308384120C111113717 @default.
• W4308384120 hasConceptScore W4308384120C112705442 @default.
• W4308384120 hasConceptScore W4308384120C126322002 @default.
• W4308384120 hasConceptScore W4308384120C126894567 @default.
• W4308384120 hasConceptScore W4308384120C197934379 @default.
• W4308384120 hasConceptScore W4308384120C2778248108 @default.
• W4308384120 hasConceptScore W4308384120C2778375690 @default.
• W4308384120 hasConceptScore W4308384120C2780580376 @default.
• W4308384120 hasConceptScore W4308384120C71924100 @default.
• W4308384120 hasConceptScore W4308384120C90924648 @default.
• W4308384120 hasConceptScore W4308384120C98274493 @default.
• W4308384120 hasLocation W43083841201 @default.
• W4308384120 hasOpenAccess W4308384120 @default.
• W4308384120 hasPrimaryLocation W43083841201 @default.
• W4308384120 hasRelatedWork W1541406077 @default.
• W4308384120 hasRelatedWork W2028648326 @default.
• W4308384120 hasRelatedWork W2112620969 @default.
• W4308384120 hasRelatedWork W2122556001 @default.
• W4308384120 hasRelatedWork W2194222775 @default.
• W4308384120 hasRelatedWork W2626992247 @default.
• W4308384120 hasRelatedWork W2922882148 @default.
• W4308384120 hasRelatedWork W2977681113 @default.
• W4308384120 hasRelatedWork W3120853613 @default.
• W4308384120 hasRelatedWork W4319063555 @default.
• W4308384120 isParatext "false" @default.
• W4308384120 isRetracted "false" @default.
• W4308384120 workType "article" @default.